The trial met its primary endpoint demonstrating a statistically significant and clinically meaningful improvement in progression free survival. The open-label, randomized ASCENT-04/KEYNOTE-D19 study ...

Enfortumab vedotin plus pembrolizumab significantly improves EFS and OS in cisplatin-ineligible MIBC patients, offering a new treatment option. The EV-303 trial is the first to show systemic treatment ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, reducing disease progression or death risk by 60%. The EV-303/KEYNOTE-905 trial ...

TOKYO, Oct. 22, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) accepted for ...

BERLIN -- Patients with cisplatin-ineligible bladder cancer had huge reductions in clinical events and cancer death when treated with a novel combination therapy before and after surgery, according to ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment significantly reduced the risk of progression or death in ...

Please provide your email address to receive an email when new articles are posted on . Survival outcomes with the sacituzumab govitecan combination outweighed outcomes with chemotherapy combination ...

Antihistamines improved OS, CSS, and PFS in mUC patients treated with Tecentriq, based on IMvigor210 and IMvigor211 trial data. A 22% reduction in cancer-specific death risk and a 29% reduction in all ...